GSK PLC (LSE:GSK, NYSE:GSK) has shared promising results from two major clinical trials (ANCHOR-1 and ANCHOR-2) testing its new treatment, depemokimab, for people suffering from chronic rhinosinusitis with nasal polyps (CRSwNP).
This condition causes painful inflammation and growths in the nasal passages, leading to breathing difficulties and other uncomfortable symptoms.
The phase III studies showed that patients who received depemokimab experienced a significant reduction in both the size of their nasal polyps and nasal blockage after 52 weeks, compared to those who received the standard-of-care plus a placebo.
Depemokimab is an advanced, long-lasting treatment that only needs to be given once every six months.
Kaivan Khavandi, GSK's head of R&D for respiratory and immunology, said: "We're very encouraged by the results from the ANCHOR studies, which demonstrate the potential for depemokimab to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction.
"Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world."